Standard BioTools Inc. (LAB) Profit Margins
Over the twelve months to 2026-06-30, Standard BioTools Inc. (LAB) had gross margin 50.5%, operating margin -112.8%, net margin 100.4%, free cash flow margin -97.6%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LABStandard BioTools Inc.Follow LAB — free
—
Price chart with a free account
- Market cap
- 237.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 69.2% | 70.7% | 74.0% | 66.1% | 62.5% | 60.6% | 55.8% | 54.6% | 54.8% | — | — | 37.8% | 47.4% | 49.3% | 49.9% | 50.5% | |
| Operating margin | -43.3% | -34.5% | -26.2% | -44.5% | -43.7% | -70.1% | -57.3% | -42.6% | -44.2% | -36.9% | -51.7% | -118.6% | -72.0% | -140.1% | -129.2% | -112.8% | |
| Net margin | -52.4% | -36.4% | -23.2% | -45.4% | -46.5% | -72.8% | -59.4% | -52.2% | -55.3% | -38.4% | -45.4% | -194.1% | -70.2% | -152.6% | -87.8% | 100.4% | |
| FCF margin | -44.8% | -38.0% | -7.1% | -25.8% | -33.7% | -42.3% | -25.2% | -22.6% | -32.2% | -20.4% | -43.9% | -95.1% | -43.4% | -166.8% | -96.9% | -97.6% |
USD millions · SEC XBRL
Standard BioTools Inc. — questions
- What is Standard BioTools Inc.'s gross margin?
- 50.5% over the twelve months to 2026-06-30.
- What is Standard BioTools Inc.'s operating margin?
- -112.8% over the twelve months to 2026-06-30.
- What is Standard BioTools Inc.'s net profit margin?
- 100.4% over the twelve months to 2026-06-30.
Every figure on this page comes from Standard BioTools Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.